Stereotaxis, Inc.
Close on Oct 19, 2026
- Market cap
- $101.03M
- P/E (TTM)
- –
- Dividend yield
- –
About Stereotaxis
Electromedical & Electrotherapeutic Apparatus, SIC 3845
Stereotaxis designs, manufactures, and markets robotic systems, instruments, and information systems for interventional laboratories. Its proprietary Robotic Magnetic Navigation technology uses computer-controlled magnetic fields to directly steer the working tip of flexible catheters and interventional devices during endovascular procedures. The company primarily focuses on electrophysiology, particularly cardiac ablation procedures to treat arrhythmias, while also developing applications for coronary, neuro, and peripheral interventions. Its product portfolio features the Genesis RMN and GenesisX RMN Systems, Synchrony and SynX cath lab display and connectivity solutions, Odyssey systems, and Map-iT diagnostic catheters. Stereotaxis operates as a single business segment, serving electrophysiologists and hospitals worldwide.
The company's systems have been deployed across more than one hundred hospitals globally, where hundreds of physicians have treated over 150,000 patients and published over 500 clinical studies. Stereotaxis maintains principal executive offices in St. Louis, Missouri, and conducts catheter operations in Rogers, Minnesota.
Summary of the business section of Stereotaxis's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Stereotaxis, Inc.
- Founded
- 1990
- Headquarters
- St.Louis, MO
- Address
- 710 N Tucker Blvd, Ste 110 63101
- Phone
- (314) 678-6100
- Website
- www.stereotaxis.com
- Employees
- 131, Dec 31, 2025
- Industry
- Electromedical & Electrotherapeutic Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, St. Louis, Missouri
Stock & identifiers
- Ticker
- STXS
- Exchange
- NYSE
- IPO date
- Aug 12, 2004
- Shares outstanding
- 100M, Jul 31, 2026
- Public float
- $150.30M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-10 reverse, Jul 11, 2012; 1-for-10 reverse, Jul 10, 2012
- SEC CIK
- 1289340
- CUSIP
- 85916J409
- ISIN
- US85916J4094
- LEI
- 549300KPNOKI02O2ZP21
- EIN
- 94-3120386
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Kimberly R. Peery | Chief Financial Officer | 3,317 |
| Myriam Curet | Director | 435,161 |
| Ross B. Levin | Director | 621,248 |
| David Benfer | Director | 771,930 |
| Arun Swarup Menawat | Director | 1,035,560 |
| Nathan Fischel | Director | 14,401,329 |
| Nachum Shamir | Director | 179,327 |
| Paul J. Isaac | Director | 2,883,856 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 David Fischel | $64.39K | -$2.04M | $326.11K | $111 | – |
| FY2024 David Fischel | $62.20K | $3.72M | $340.17K | $112 | – |
| FY2023 David Fischel | $62.20K | -$4.29M | $323.80K | $85 | – |
| FY2022 Mr. David Fischel | $62.20K | -$49.09M | $386.76K | $33 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“of December 31, 2025, we had 131 employees, 40 of whom were engaged directly in research and development, 47 in sales and marketing activities,”
Corporate history
Events identified from SEC filings